Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Association of British Healthcare Industries (ABHI) questions drug authority involvement

This article was originally published in Clinica

Executive Summary

The UK Association of British Healthcare Industries is arguing against the Medicines Control Agency's level of proposed consultation fees for well-established drug-device combinations. It is drawing up a list of combination products where medicinal substances are ancillary to devices for which, in its opinion, consultation and therefore fees should be minimal (or not even necessary).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT091925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel